Caroline Robert, MD, PhD, from the Gustave Roussy Cancer Campus in Paris, France, provides her take on the most important and clinically relevant studies on melanoma that were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The conference was held online because of the COVID-19 pandemic.
First, Dr Robert discusses two studies in treatment-naive patients with advanced melanoma. COMBI-i looked at spartalizumab plus dabrafenib and trametinib, while SECOMBIT examined the sequencing of targeted therapy and immunotherapy, both in patients with BRAF V600 mutations.
Next, she turns to a pooled analysis of data from CheckMate 066 and 067. This study of factors predicting 5-year survival of melanoma patients treated with immunotherapy suggested that a complete response at 1 year may be key.
The combination of lenvatinib and pembrolizumab in melanoma patients who have progressed after immunotherapy is the next trial that Dr Robert highlights. The results from LEAP-004 suggest that the combination therapy may offer hope to this population with a high unmet clinical need.
Finally, Dr Robert discusses CheckMate 238 and KEYNOTE-054, two studies of immunotherapy in the adjuvant setting for high-risk patients. In both trials, patients experienced meaningful improvements in survival outcomes.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author’s own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Breakthroughs in Melanoma From ESMO Virtual Congress 2020 – Medscape – Oct 12, 2020.